SOUTH SAN FRANCISCO, Calif., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), a clinical-stage biopharmaceutical company developing novel therapies for cancer, today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will be presenting at the Stifel Healthcare Conference on November 16, 2016, at 8:00 a.m. Eastern Time. A live audio webcast of the presentation will be available in the "Investors" section of Threshold's website, www.thresholdpharm.com. A replay of the presentation will be archived for 30 days following the conference. About Threshold Pharmaceuticals Threshold is a clinical-stage biopharmaceutical company focused on the development of drugs and diagnostic agents targeting the tumor microenvironment of solid tumors and hematologic malignancies. This approach offers broad potential to treat a variety of cancers. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit the Company's website.
Contact:Denise Powell firstname.lastname@example.org 510.703.9491